Jennifer Riggs, MD
Interventional Cardiology · Saint Paul, MNNPI 1962812636
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (50.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 71.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $9,067 and has fallen 86.6% since, to $1,219 in 2025.
Across 134 payments — averaging $126.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Edwards Lifesciences$1K
- Boston Scientific$1K
- Abiomed$808
- Abbott$588
- Irhythm Technologies, Inc.$179
- plus $863 from 12 others
What the payments were for
- Grants$8,60551%
- Travel & lodging$3,44920%
- Food & beverage$4,51027%
- Education$4032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 67 | $12,045 |
| Edwards Lifesciences | 23 | $1,345 |
| Boston Scientific | 4 | $1,139 |
| Abiomed | 4 | $808 |
| Abbott | 7 | $588 |
| Irhythm Technologies, Inc. | 6 | $179 |
| Amgen | 11 | $170 |
| Acist Medical Systems, Inc. | 2 | $133 |
| Cardiovascular Systems Inc. | 1 | $120 |
| Shockwave Medical, Inc | 1 | $106 |
| Astellas Pharma US Inc | 1 | $90 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $83 |
| Chiesi USA, Inc. | 1 | $47 |
| Novo Nordisk | 1 | $32 |
| Sanofi | 1 | $26 |
| Cardiva Medical, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,968 in reported general payments places this provider in the 70th percentile of 84 interventional cardiology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 36 | $32,855 |
| Atorvastatin Calcium | 53 | $507 |
| Metoprolol Succinate | 40 | $456 |
| Ezetimibe | 16 | $456 |
| ClopidogrelClopidogrel Bisulfate | 30 | $352 |
| Carvedilol | 38 | $202 |
| Amlodipine Besylate | 22 | $187 |
| Spironolactone | 24 | $106 |
| Furosemide | 29 | $105 |
| Losartan Potassium | 31 | $101 |
| Rosuvastatin Calcium | 15 | $75 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Saint Paul
- Brett OestreichSaint Paul$26K
- Marat YanavitskiSaint Paul$21K
- Bilal MuradSaint Paul$17K
- Kenneth BaranSaint Paul$16K
- Abdalla HassanSaint Paul$9K
- Marit ThorsgardSaint Paul$9K
- James KolbeckSaint Paul$5K
- Thom DahleSaint Cloud$1.1M
- Stephen KiddSaint Cloud$607K
- Brian StegmanSt Cloud$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.